After once claiming his shots are "100 effective," Pfizer CEO now says 2 COVID shots "offers very limited protection, if any," against COVID-19.

Effective?

During a round of interviews on Monday, Pfizer CEO Albert Bourla unleashed several truth bombs on an unsuspecting corporate press audience, seemingly sowing doubt into the idea that his own COVID shots are “effective,” unless the individual has had at least 3 doses.

Tyler Carditis @TyCardon

Pfizer CEO: “Two doses of the vaccine offers very limited protection, if any. 3 doses with a booster offer reasonable protection against hospitalization and deaths. Less protection against infection.” @US_FDA -Come get your boy!

[An earlier version of this post misinterpreted Pfizer CEO Albert Bourla’s English. It seemed like he was sowing doubt about the safety of his own COVID shots. Instead, he was alluding to a “safety profile” issue regarding his competitor’s current shingles vaccination (Shingrix is made by Pfizer competitor GSK and it has 90% market share), which he claimed can be solved with mRNA.]

The Pfizer chief appeared on Squawk Box this morning after the company announced several agreements in the fields of gene editing, with the hopes to use these technologies to bolster the mRNA platform for their COVID shots.

Yes, Pfizer is seeking partners in order to explore ways to actively change people’s DNA. This idea, if you recall, was once dismissed by the corporate press as an unhinged conspiracy theory.

But that was only half the story.

Seemingly hooked to a truth serum device, the Pfizer CEO then said in a Yahoo finance interview that two Pfizer mRNA shots — which he once claimed were 100% effective at preventing the disease — now only “offers very limited protection, if any.”

Albert Bourla @AlbertBourla

Excited to share that updated analysis from our Phase 3 study with BioNTech also showed that our COVID-19 vaccine was 100% effective in preventing #COVID19 cases in South Africa. 100%!

pfizer.comPfizer and BioNTech Confirm High Efficacy and No Serious Safety Concerns Through Up to Six Months Following Second Dose in Updated Topline …Analysis of 927 confirmed symptomatic cases of COVID-19 demonstrates BNT162b2 is highly effective with 91.3% vaccine efficacy observed against COVID-19, measured seven days through up to six months after the second dose Vaccine was 100% effective in preventing severe disease as defined by the U.S. C…

He said this in the context of pushing for a new round of shots for the Omicron variant.

Truly, unbelievable stuff. In a series of interviews, Bourla attempted to change the entire COVID narrative, while simultaneously sowing incredible doubt about the efficacy of his current product line up.

Here’s the link to the full CNBC interview.

Check out our loyal sponsor:

TrustCapital is the #1 Bitcoin and precious metals IRA/401K platform in America. Sign up using my promo code DOSSIER and you will receive the benefits of tax-free investing and trading with ZERO MONTHLY FEES! Linked here and in the banner.